相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
Piyada Sitthideatphaiboon et al.
SCIENTIFIC REPORTS (2022)
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
Simon Baldacci et al.
EUROPEAN JOURNAL OF CANCER (2022)
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
Carolina Nunes et al.
SCIENCE ADVANCES (2022)
Inhibiting RRM2 to enhance the anticancer activity of chemotherapy
Yaqiong Zhan et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L)
Maria Rosario Garcia Campelo et al.
LUNG CANCER (2021)
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
Joanna Szydzik et al.
NATURE COMMUNICATIONS (2021)
RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma
Xueping Jiang et al.
CELL AND BIOSCIENCE (2021)
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK plus ) NSCLC
Shannon S. Zhang et al.
LUNG CANCER (2021)
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
Liselot M. Mus et al.
SCIENTIFIC REPORTS (2020)
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
Kang Qin et al.
BMC CANCER (2020)
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Ying Z. Mazzu et al.
MOLECULAR ONCOLOGY (2020)
ARID1Amutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis
Yin P. Hung et al.
MODERN PATHOLOGY (2020)
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
Lucas Moreno et al.
EUROPEAN JOURNAL OF CANCER (2020)
High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma
Cheng-Yu Jin et al.
Aging-US (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Independent prognostic implications of RRM2 in lung adenocarcinoma
Chao Ma et al.
JOURNAL OF CANCER (2020)
Targeting anaplastic lymphoma kinase in neuroblastoma
Ganesh Umapathy et al.
APMIS (2019)
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK plus Lung Cancer
Leora Horn et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
Ji-Hyun Kwon et al.
CELLS (2019)
Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
Seok-Young Kim et al.
SCIENTIFIC REPORTS (2019)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer
Petros Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis
Lucille Lopez-Delisle et al.
ONCOGENE (2018)
Triapine Radiochemotherapy in Advanced Stage Cervical Cancer
Charles A. Kunos et al.
Frontiers in Oncology (2018)
TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer
D. B. Costa
ANNALS OF ONCOLOGY (2018)
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
Jimmy Van den Eynden et al.
SCIENCE SIGNALING (2018)
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
C. G. Woo et al.
ANNALS OF ONCOLOGY (2017)
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Ka-Won Noh et al.
JOURNAL OF PATHOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
P53 suppresses ribonucleotide reductase via inhibiting mTORC1
Zhengfu He et al.
ONCOTARGET (2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Sarah R. Sabir et al.
CANCERS (2017)
Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications
Xiaoyu Chen et al.
BIOINFORMATICS (2016)
Canvas: versatile and scalable detection of copy number variants
Eric Roller et al.
BIOINFORMATICS (2016)
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer
Amanda J. Redig et al.
CLINICAL CANCER RESEARCH (2016)
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
Tatsuya Yoshida et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic et al.
NATURE MEDICINE (2015)
HISAT: a fast spliced aligner with low memory requirements
Daehwan Kim et al.
NATURE METHODS (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
Y. Aye et al.
ONCOGENE (2015)
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly et al.
NATURE MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
GENCODE: The reference human genome annotation for The ENCODE Project
Jennifer Harrow et al.
GENOME RESEARCH (2012)
Oncogenic Fusions Involving Exon 19 of ALK
Anh T. Le et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2011)
siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide
Jonathan E. Zuckerman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Structural biology of the tumor suppressor p53
Andreas C. Joerger et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors:: Four cases of homozygous deletions of the CDKN2A gene
Helena Caren et al.
BMC GENOMICS (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress
Z. Ping Lin et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
Laurence Lamant et al.
BLOOD (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays
Y Nannya et al.
CANCER RESEARCH (2005)
MDM2 gene amplification:: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)
D Dworakowska et al.
LUNG CANCER (2004)
Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing
ZY Jiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation
A Arcaro et al.
EMBO JOURNAL (2002)
Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors
A Arcaro et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
